Silence Therapeutics appoints Romano as Incoming Chief Medical Officer

Silence Therapeutics (SLN) announced the appointment of Steven Romano, MD, as incoming Chief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&D at Silence, to ensure an efficient and smooth transition for Dr. Campion’s retirement by year-end. Dr. Romano has served as non-executive director of the Silence Board since July 2019 following the Company’s siRNA collaboration with Mallinckrodt plc for complement-mediated diseases. Most recently, Romano served as executive vice president and chief scientific officer at Mallinckrodt (MNK) and was responsible for research and development, medical affairs, health economics and outcomes research, safety, pharmacovigilance and regulatory affairs functions.